Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

0.48$0.00 0.59%
Market open       15:32:32 pm   

Stock Snapshot

0.48
Prev. Close
0.48
Open
63.46M
Market Cap
89910.00
Number of Shares
0.4566
Day Low
0.4806
Day High
0.48
-
P/E Ratio
129.71M
Free Float in %
-0.31
EPS 2021
0.58
Book Value per Share
0.56
Cash Flow per Share
Synthetic Biologics, Inc. (SYN)
Synthetic Biologics, Inc. (SYN) stock rallied over 0.59% intraday to trade at $0.48 share on AMEX. The stock opened with a fall of % at $0.48 and touched an intraday high of $0.4806, rising 0.13% against the last close of $0.48. The stock went to a low of $0.4566 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$0.48$0.51$0.56$0.4811,901,399
2021-09-03$0.50$0.51$0.52$0.5081,690,000
2021-09-02$0.49$0.52$0.53$0.49195,600,000
2021-09-01$0.49$0.49$0.49$0.4873,050,000
2021-08-31$0.48$0.48$0.49$0.4777,850,000
2021-08-30$0.49$0.48$0.50$0.4856,510,000
2021-08-27$0.48$0.49$0.50$0.47142,900,000
2021-08-26$0.49$0.48$0.50$0.47150,530,000
2021-08-25$0.47$0.49$0.50$0.46105,780,000
2021-08-24$0.45$0.48$0.48$0.45147,540,000
2021-08-23$0.45$0.45$0.46$0.4492,160,000
Synthetic Biologics, Inc.
9605 Medical Center Drive
Suite 270
Rockville, MD 20850
United States

http://www.syntheticbiologics.com
301 417 4364
Employees
10
Sector
Healthcare
Sales or Revenue
-
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30

Synthetic Biologics, Inc.
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam